A Phase 2, Multicenter, Randomized Open-Label Study to Determine the Efficacy of Lenalidomide (Revlimid) Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2018
At a glance
- Drugs Lenalidomide (Primary) ; Chlorambucil; Cytarabine; Fludarabine; Fludarabine; Gemcitabine; Rituximab
- Indications Mantle-cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms SPRINT
- Sponsors Celgene Corporation
- 03 Aug 2018 This trial has been completed in Czech Republic, according to European Clinical Trials Database.
- 28 Jul 2018 This trial has been completed in Germany, according to European Clinical Trials Database.
- 24 Apr 2018 Planned End Date changed from 28 Mar 2018 to 5 Jul 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History